St Germain D J Co Inc buys $756,620 stake in Celgene Corporation (CELG)

Celgene Corporation (CELG) : St Germain D J Co Inc scooped up 2,947 additional shares in Celgene Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 21, 2016. The investment management firm now holds a total of 6,846 shares of Celgene Corporation which is valued at $756,620.Celgene Corporation makes up approximately 0.11% of St Germain D J Co Inc’s portfolio.

Celgene Corporation closed down -1.4 points or -1.30% at $106.15 with 59,08,642 shares getting traded on Wednesday. Post opening the session at $107.9, the shares hit an intraday low of $105.82 and an intraday high of $108.11 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

Other Hedge Funds, Including , Bridges Investment Management Inc reduced its stake in CELG by selling 6,173 shares or 5.2% in the most recent quarter. The Hedge Fund company now holds 112,511 shares of CELG which is valued at $12,434,716. Celgene Corporation makes up approx 2.18% of Bridges Investment Management Inc’s portfolio.Lebenthal Holdingsllc boosted its stake in CELG in the latest quarter, The investment management firm added 6,185 additional shares and now holds a total of 20,671 shares of Celgene Corporation which is valued at $2,284,559. Celgene Corporation makes up approx 0.39% of Lebenthal Holdingsllc’s portfolio.

On the company’s financial health, Celgene Corporation reported $1.18 EPS for the quarter, missing the analyst consensus estimate by $ -0.03 based on the information available during the earnings call on Jan 28, 2016. Analyst had a consensus of $1.21. The company had revenue of $2563.30 million for the quarter, compared to analysts expectations of $2548.22 million. The company’s revenue was up 22.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.01 EPS.

Many Wall Street Analysts have commented on Celgene Corporation. Citigroup Initiated Celgene Corporation on Feb 25, 2016 to “Buy”, Price Target of the shares are set at $130.Shares were Reiterated by RBC Capital Mkts on Jan 29, 2016 to “Outperform” and Lowered the Price Target to $ 135 from a previous price target of $150 .

Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Company’s primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.

Leave a Reply

Celgene Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Celgene Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.